NMN and NAD+ Human Clinical Trials in 2026: A Ready-to-Use Evidence Summary
Neil Tuckwell·Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.··9 min read
NMN and NAD+ Human Clinical Trials in 2026: A Ready-to-Use Evidence Summary
There is a molecule in your cells that every metabolic process depends on, and it quietly drops by around half between your twenties and your sixties. That molecule is NAD+, and the supplement industry has built a billion-dollar category around a precursor called NMN, promising to top it back up. But what does the actual clinical trial data say in 2026? Here is an honest, scannable evidence summary so you can judge for yourself. For broader context on the longevity supplement landscape, see our longevity supplements science overview.
What NMN and NAD+ Actually Are
NAD+ stands for nicotinamide adenine dinucleotide, a coenzyme found in every living cell. Think of it as the cell's universal energy currency and a critical signaling molecule at the same time. It fuels the sirtuins, the protein family most associated with longevity research, and it powers the PARP enzymes that repair broken DNA. When NAD+ levels fall with age, these repair and signaling systems run at a lower capacity.
NMN, short for nicotinamide mononucleotide, is a direct biochemical precursor to NAD+. You take NMN orally, it is absorbed in the gut, and the body converts it into NAD+ in a single enzymatic step. The idea is simple: feed the pathway and replenish what aging drains. What makes NMN particularly interesting to researchers is that it is a naturally occurring compound, found in small amounts in foods like edamame and broccoli, so there is a plausible physiological rationale for supplementation.
The central research question has always been whether boosting NAD+ by this route actually changes anything meaningful in the body. Raising a biomarker is one thing. Improving how you walk, sleep, or metabolize sugar is quite another. The trials through 2026 have started to draw a clearer line between what NMN does reliably and what it does not yet convincingly deliver.
What the 2026 Trial Landscape Actually Shows
If you want the honest one-paragraph verdict before reading any further, here it is. NMN reliably raises blood NAD+ levels in humans, and that part of the story is settled. The downstream clinical benefits, meaning the effects on your glucose, cholesterol, muscle mass, or grip strength, are far more mixed. Some measures look promising. Others show no significant effect compared to placebo. The field is real, the biology is fascinating, and the oversell is almost universal. The data is not.
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
NT
Neil Tuckwell
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
Science writer covering the biology of aging. Turns cutting-edge anti-aging research into stories you'll want to read over morning coffee.
NMNNAD+clinical trialslongevity
Related Articles
nicotinamide mononucleotide
Clinical Trials
How to Evaluate Health Claims on Supplement Labels
How to evaluate supplement health claims: claim types, third-party certification, red flags, and evidence assessment to make informed choices.
Katie Brouwer·10 min read
The most comprehensive synthesis available as of 2026 is a meta-analysis by Zhang and colleagues published in Critical Reviews in Food Science and Nutrition, which pooled 12 randomized controlled trials covering 513 participants[1]. The headline finding was that NMN supplementation significantly elevated NAD+ concentrations. That is the consistent signal across essentially every well-run trial. The second headline, which gets far less supplement-brand airtime, is that NMN produced no statistically significant improvements in fasting glucose, insulin sensitivity, HbA1c, or lipid markers compared to placebo.
A companion meta-analysis from Chen and colleagues in Current Diabetes Reports reached the same conclusion from a slightly different pool of eight RCTs with 342 participants[2]. Doses ranged from 250mg to 2,000mg per day across trial durations of two weeks to twelve weeks. Across all of them, the metabolic markers that matter clinically, fasting glucose, HOMA-IR, HbA1c, total cholesterol, LDL, and triglycerides, did not shift meaningfully versus placebo in healthy adults. The authors were careful to note this conclusion applies specifically to healthy adults without metabolic disease, which is who most trial participants were.
Where the Evidence Is Actually Encouraging
Step back from the metabolic endpoints, and a different picture emerges. Physical performance, particularly walking-related measures in older adults, is where the NMN trial data looks more interesting. A systematic review by Wang and colleagues covering nine RCTs with 412 participants found a statistically significant improvement in gait speed with an SMD of 0.34 m/s (p<0.05), alongside a meaningful reduction in ALT liver enzyme levels[3]. These are not massive effect sizes, but they clear the threshold of statistical significance in a pooled analysis.
Individual trials add texture to this picture. Lin Yi and colleagues ran a multicenter, double-blind, placebo-controlled RCT in 80 healthy adults aged 40 to 65, testing doses of 300mg, 600mg, and 900mg for 60 days[6]. NAD+ increased significantly at all doses (p<0.001). The six-minute walking distance improved significantly (p<0.01). And perhaps most intriguing: biological age, as measured by established blood-based algorithms, remained stable in NMN groups while it increased in the placebo group (p<0.05). That last finding is preliminary and deserves replication, but it is the kind of result that justifies continued research attention.
Morifuji and colleagues added another dimension in a 2024 double-blind RCT in 60 older adults over twelve weeks[7]. At a relatively modest dose of 250mg per day, participants showed significantly shorter four-meter walking time versus placebo (p<0.05), elevated NAD+ levels (p<0.05), and improved sleep quality as measured by the Pittsburgh Sleep Quality Index daytime dysfunction subscale (p<0.05). Sleep is rarely a primary endpoint in NMN trials, which makes this a genuinely interesting secondary finding. Whether it replicates at scale is the open question.
Where the Evidence Is Weak or Inconsistent
Muscle mass and strength are where NMN's clinical story gets complicated. A 2025 meta-analysis by Prokopidis and colleagues published in the Journal of Cachexia, Sarcopenia and Muscle looked specifically at skeletal muscle outcomes in older adults with a mean age over 60[4]. The findings were clear and null: no significant effect on skeletal muscle index (SMI MD -0.42, p=0.14), no significant change in handgrip strength, and no significant improvement in gait speed (MD -0.01, p=0.79). This directly conflicts with the Wang meta-analysis cited above, and that conflict is itself informative.
The discrepancy between these two meta-analyses likely reflects differences in which trials were included, how outcomes were operationalized, and which participant populations were prioritized. This is not unusual in early-stage clinical literature. The Wen et al. systematic review of ten RCTs in 437 patients found non-significant improvements in grip strength of about 0.6 kg, which is a trend in the right direction that does not reach statistical significance[5]. Taken together, the muscle and strength data suggests NMN is not doing nothing, but the effect is not robust enough to show up consistently across analyses.
The metabolic null results deserve additional emphasis because they affect one of the most common reasons people take NMN. The two large meta-analyses[1][2] covering hundreds of participants are reasonably powered and consistent with each other. They do not find a meaningful effect on the glucose or lipid parameters that define cardiometabolic risk in healthy adults. It is still possible that people with existing metabolic impairment respond differently, since most trials explicitly enrolled healthy participants. That is a research gap, not evidence of benefit. The evidence simply does not yet exist for that population.
Safety: The Clearest Finding in the Literature
On the question of safety, the clinical trial data is actually quite consistent, and the news is reassuring. Across doses ranging from 250mg to 1,250mg per day and trial durations up to twelve weeks, no serious adverse events have been reported in any of the published RCTs. Fukamizu and colleagues specifically ran a safety-focused RCT at the highest dose tested in any published trial, 1,250mg per day for four weeks in 31 adults aged 20 to 65[9]. Hematology, biochemistry, and physiological measures all remained within clinically normal ranges. No participant experienced a serious adverse event.
Katayoshi and colleagues, in a 2023 double-blind placebo-controlled trial using 250mg per day for twelve weeks, found significant elevation of serum nicotinamide alongside a non-significant trend toward lower arterial stiffness, with no adverse events recorded[8]. This trial is notable because arterial stiffness is a meaningful cardiovascular aging biomarker, and the trend, while not statistically significant, is physiologically plausible given NAD+'s role in sirtuin and PARP activity in vascular tissue. A larger, adequately powered trial on vascular endpoints would be genuinely informative.
One important nuance from the safety and pharmacokinetics literature comes from a 2025 post-hoc analysis by Kuerec and colleagues, which found striking individual variability in NAD+ response to NMN supplementation[10]. Across 80 adults with a mean age of 49.4 years, the coefficient of variation in NAD+ response ranged from 29.2% to 113.3%. That means some people triple their NAD+ from supplementation while others barely move. This variability has practical implications: a trial that shows "no significant effect" on an outcome might contain strong responders whose signal is buried in non-responder noise. It also means population-level conclusions may not predict your individual response.
Practical Dosing: What the Trials Actually Used
If you are trying to understand what dosing the human evidence is built on, here is a direct summary from the published trials. For a practical guide to selecting an NMN supplement, see how to choose an NMN supplement. The most commonly tested dose is 250mg per day, which appears in at least three independent trials[7][8][10]. This is the conservative end of the range and appears in trials showing both NAD+ elevation and modest functional improvements. The Lin Yi multicenter trial tested 300mg, 600mg, and 900mg per day, and all three doses showed significant NAD+ increases with a dose-response relationship[6].
The highest dose with published safety data is 1,250mg per day for four weeks, which Fukamizu and colleagues confirmed was well-tolerated[9]. The meta-analyses synthesize trials using doses from 250mg to 2,000mg per day, though the 2,000mg data point is from a shorter-duration study[2]. What the data cannot yet tell you is whether higher doses produce meaningfully better clinical outcomes, since no head-to-head dose comparison has been adequately powered for functional endpoints. The pharmacology suggests a ceiling effect is plausible once NAD+ synthesis capacity is saturated, but that ceiling has not been empirically located in humans.
Duration is the other variable. Most trials run for 8 to 12 weeks, which is enough to see NAD+ elevation but may not be enough to detect changes in slower-moving outcomes like muscle mass or vascular function. This is a genuine limitation of the current literature, and longer trials are needed before null results on slower endpoints should be interpreted as definitive. The Kuerec analysis of individual NAD+ variability also raises the question of whether some trial durations are long enough to overcome intra-individual noise in response[10]. These are open scientific questions, not settled ones.
Frequently Asked Questions
Q. Does NMN actually raise NAD+ levels in humans?
Yes, this is the most consistently replicated finding across the clinical trial literature. Multiple meta-analyses and individual RCTs confirm that oral NMN supplementation significantly elevates blood NAD+ concentrations in adults across a range of doses from 250mg to 1,250mg per day. The effect is dose-responsive and appears within days of supplementation. What remains less clear is exactly how much NAD+ needs to rise, and in which tissues, to produce meaningful health outcomes.
Q. Does NMN improve muscle strength or mass?
The evidence here is inconsistent and, on balance, not convincing for muscle mass. The Prokopidis meta-analysis found no significant effect on skeletal muscle index, handgrip strength, or gait speed in older adults[4]. A separate meta-analysis found significant improvement in gait speed[3], which suggests the true effect, if any, is small and depends heavily on which trials and outcome measures are included. Grip strength showed a non-significant trend toward improvement in some analyses[5]. This area needs larger, longer, and better-standardized trials before strong conclusions are possible.
Q. Is NMN safe to take?
Based on published clinical trial data through 2026, NMN appears well-tolerated at doses up to 1,250mg per day for at least four weeks. No serious adverse events have been reported in any published RCT. Longer-term safety data beyond twelve weeks in controlled trial settings is limited, so the long-term profile in humans is not fully characterized. As with any supplement, individual circumstances and existing health conditions matter, and a conversation with a qualified healthcare provider is appropriate before starting.
Q. What health benefits does NMN have the strongest clinical evidence for?
The strongest functional evidence relates to walking speed and physical performance in older adults. Two independent trials found significant improvements in walking-related measures[6][7], and one meta-analysis found a statistically significant gait speed improvement[3]. Sleep quality improvement appeared as a secondary finding in one trial[7] and warrants further study. Metabolic outcomes including glucose, insulin, and lipids have not shown significant benefit in the largest meta-analyses to date[1][2].
Q. What dose of NMN was used in the trials?
Trials have used doses ranging from 250mg to 2,000mg per day. The most commonly studied dose in individual RCTs is 250mg per day. The multicenter Lin Yi trial tested 300mg, 600mg, and 900mg and found dose-dependent NAD+ increases with functional improvements[6]. The highest dose with published safety data is 1,250mg per day for four weeks[9]. No published trial has directly compared dose levels for functional outcomes in an adequately powered design.
References
[1] Zhang et al., "Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials," Critical Reviews in Food Science and Nutrition, 2025. DOI: 10.1080/10408398.2024.2387324
[2] Chen et al., "Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials," Current Diabetes Reports, 2024. DOI: 10.1007/s11892-024-01557-z
[3] Wang et al., "Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of Randomized Controlled Trials," Current Pharmaceutical Biotechnology, 2025. DOI: 10.2174/0113892010306242240808094303
[4] Prokopidis et al., "The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis," Journal of Cachexia, Sarcopenia and Muscle, 2025. DOI: 10.1002/jcsm.13799
[5] Wen et al., "Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials," Cureus, 2024. DOI: 10.7759/cureus.65961
[6] Lin Yi et al., "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial," Geroscience, 2023. DOI: 10.1007/s11357-022-00705-1
[7] Morifuji et al., "Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study," Geroscience, 2024. DOI: 10.1007/s11357-024-01204-1
[8] Katayoshi et al., "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial," Scientific Reports, 2023. DOI: 10.1038/s41598-023-29787-3
[9] Fukamizu et al., "Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women," Scientific Reports, 2022. DOI: 10.1038/s41598-022-18272-y
[10] Kuerec et al., "Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial," Geroscience, 2025. DOI: 10.1007/s11357-025-01968-0
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
